Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000642355 | SCV000764024 | uncertain significance | MHC class I deficiency | 2021-09-26 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with TAP1-related conditions. This variant is present in population databases (rs756823000, ExAC 0.001%). This sequence change replaces asparagine with lysine at codon 461 of the TAP1 protein (p.Asn461Lys). The asparagine residue is moderately conserved and there is a moderate physicochemical difference between asparagine and lysine. |
Center for Genomics, |
RCV000642355 | SCV001190469 | uncertain significance | MHC class I deficiency | 2021-03-30 | criteria provided, single submitter | clinical testing | TAP1 NM_000593.5 exon 5 p.Asn461Lys (c.1383C>G): This variant has not been reported in the literature but is present in 0.001% (2/113768) of European alleles in the Genome Aggregation Database (https://gnomad.broadinstitute.org/variant/6-32818142-G-C). This variant is present in ClinVar (Variation ID:534703). Evolutionary conservation suggests that this variant may not impact the protein; computational predictive tools suggest that this variant may impact the protein. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. |